USP22 and cancer: IHC analysis showed that USP22 was undetectable (scored as 0, Fig. 1b) in 33.2% (67/202), while USP22 levels in 17.8% (36/202), 27.7% (56/202), and 21.3% (43/202) of cancer cases were scored as 1+ (Fig. 1c), 2+ (Fig. 1d), 3+ (Fig. 1e) respectively.